About this episode

The episode discusses the first large phase 3 trial of an oral GLP-1 for type 2 diabetes and obesity, along with related studies and guidelines.

This week on This Week in Diabetes & Endocrinology, from Hormone Insight: the first large phase 3 trial of an oral GLP-1, orforglipron, in adults with type 2 diabetes and obesity (ATTAIN-2, Lancet). The headline is not the size of the weight loss. It is the word oral. Also this week: - A 112,000-patient ACP network meta-analysis that keeps semaglutide and tirzepatide on top for both weight loss and cardiovascular outcomes - A provocative real-world comparison of bariatric surgery versus semaglutide in fatty liver disease - The 2026 ADA Standards of Care, which make cardiovascular and kidney protection a co-primary goal alongside A1C - A Hormone Classic revisit of UKPDS that explains why that shift had to happen One question runs through all of it: does this change Monday clinic? Chapters 00:00 Cold open 00:42 This week 01:13 Trial of the Week: orforglipron (ATTAIN-2) 04:29 Quick Hit: ACP weight-loss drug meta-analysis 05:21 Quick Hit: surgery vs semaglutide (MASLD) 06:21 Guideline & FDA Watch: 2026 ADA Standards 07:27 Hormone Classics: UKPDS 08:26 The Bottom Line 08:57 Sign-off References and written summary: hormoneinsight.com/[slug] For healthcare professionals. Educational…

More episodes of Hormone Insight

• STEP 1 Trial Explained: Semaglutide 2.4 mg for Obesity in 2 Minutes · June 28, 2026 · 2 min
• Jun 27, 2026: This Week in Diabetes & Endocrinology -- The triple agonist arrives, and the bar moves · June 27, 2026 · 12 min

Explore listener stats, chart rankings, contacts and more on the Hormone Insight podcast page.